Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …

Brain metastasis from non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) mutations is a hot research topic, but also a difficulty in targeted NSCLC …

The most effective treatment approach for brain metastases in patients with non-small cell
lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations is a …

Brain metastasis is a serious complication of non-small cell lung cancer (NSCLC) affecting
up to 40% of NSCLC patients. A subset of NSCLC tumors has mutations in the epidermal …

Brain parenchymal metastasis from a solid tumor is a serious clinical condition associated
with a poor outcome because systemic chemotherapy is usually ineffective for treating brain …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …

Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …

A considerable proportion of non-small-cell lung cancer (NSCLC) patients will develop
central nervous system (CNS) metastases throughout the course of their disease and these …